You just read:

FDA Expands IMBRUVICA® (ibrutinib) Label to Include New Data from Two Key Phase 3 Trials, Adding Overall Survival and Combination Data

News provided by

Janssen Biotech, Inc.

09 May, 2016, 08:16 ET